Gautam Chukka

Gautam Chukka Analyst Performance

Director, Biotech Equity Research at Chardan Capital

Gautam Chukka is a stock analyst at Chardan Capital in the healthcare sector, covering 5 publicly traded companies. Over the past year, Gautam Chukka has issued 9 stock ratings, including buy and hold recommendations. While full access to Gautam Chukka's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Gautam Chukka's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
9 Last 0 Years
Buy Recommendations
88.89% 8 Buy Ratings
Companies Covered
5 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy88.9%8 ratings
Hold11.1%1 ratings
Sell0.0%0 ratings

Out of 9 total stock ratings issued by Gautam Chukka at Chardan Capital, the majority (88.9%) have been Buy recommendations, followed by 11.1% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
5 companies

Gautam Chukka, an analyst at Chardan Capital, currently covers 5 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
5 companies
100.0%

Gautam Chukka of Chardan Capital specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
3 companies
60.0%
PHARMACEUTICALS
2 companies
40.0%

Gautam Chukka's Ratings History at Chardan Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
10/28/2026Reiterated Rating$132.91$240.00Buy
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
10/28/2026Reiterated Rating$2.58$9.00Buy
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
10/20/2026Initiated Coverage$0.97Buy
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
10/6/2026Lower Price Target$12.92$25.00Buy
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
9/10/2026Initiated Coverage$3.27$9.00Buy
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
8/11/2026Downgrade$1.68$5.00Neutral
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
7/31/2026Reiterated Rating$14.61$27.00Buy
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
7/2/2026Reiterated Rating$13.29$27.00Buy
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
6/22/2026Initiated Coverage$12.00$27.00Buy